Establishing a Sales Structure for Exosome Purification Kits (Research Use)
First written in FY2019-Q3. 2 of 6 entries say "Restated". Latest entry: FY2024.
0 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「By segment, in the Advanced R&D Support Business, R&D expenses totaled ¥65.801 million, due mainly to efforts to strengthen coordination between production and development and promote production technology development. In the Healthcare Solutions Business, R&D expenses totaled ¥115.688 million, due mainly to research and development activities related to clinical research and exosome purification aimed at the practical application and commercialization of the comprehensive support service for functional material development.」
The Company continues R&D related to healthcare, including functional material development, clinical research and exosome purification. - FY2023-Q3RestatedAnnual report
「We also promoted research and development of new businesses for healthcare-related companies, resulting in higher research and development expenses.」
The Company is promoting sales expansion for the exosome purification column and continues its sales efforts following the launch of the new product in December 2022. - FY2023-Q2ReframedAnnual report
「As one result of joint research related to exosomes, the Company launched a new exosome purification column product in December 2022.」
The content shifted from the exosome purification kits, whose sales had previously ceased to be mentioned, to the development of a related but different product, the launch of a new exosome purification column. - FY2020DroppedAnnual report
「We also worked on business development and research and development for new pipelines and biomarker-related businesses.」
The current year's main text does not explicitly mention the name or continued sales of the research-use exosome purification kits, reverting to the general expression biomarker-related business. - FY2019AdvancedAnnual report
「The Company also explored new pipelines and biomarker-related businesses and began selling research-use exosome purification kits.」
The Company progressed from establishing a sales structure to commencing sales of research-use exosome purification kits. - FY2019-Q3First statedAnnual report
「We also worked on considering new pipelines and biomarker-related businesses and established a sales structure for a research-use exosome purification kit.」
The Company has for the first time described the establishment of a sales structure for research-use exosome purification kits as a specific initiative.